BrightSpring Grew EBITDA 42% and the Stock Yawned — Read the Q&A Instead
A per-script metric unveiled and instantly disclaimed, home & community pharmacy flipped from IRA victim to growth engine, and a $400 million M&A line thrown away in passing.
BTSG · Earnings Call · 2026-10-30
The beat that didn't move the tape
BrightSpring's third quarter was, on the numbers, the best kind of quarter a roll-up can print. Revenue of $4.2 billion, up 26%. Adjusted EBITDA of $228 million, up 42%. Adjusted EPS of $0.54, up 80% year over year and 20% sequentially. Operating cash flow above $200 million, and net leverage down to 1.79x against a stated 2.5x target. Guidance went up, not sideways: full-year adjusted EBITDA of $850–860 million, which is 37.6% to 39.3% growth, with revenue of $15.9 billion to $16.125 billion. And the stock has done nothing. BTSG is down about 4% over the last 90 trading days and sits 8.3% below its July 24 high of $72.91, despite being up more than 500% since its January 2024 IPO. That gap — the operating machine versus the flat tape — is the real subject of this call. After two years of multiple expansion (the shares now fetch roughly 1.0x revenue versus a fraction of that at listing), the market has stopped paying for growth and started underwriting the 2027 model.The per-script pirouette
The most revealing moment came forty seconds into Q&A. Whit Mayo asked about the acceleration in gross profit per script. Jennifer Phipps disclosed two numbers never before aired — “Revenue per script in the quarter was $340.86. Up 24% year over year with gross profit per script of $28.86, up 27% year over year.” — Jennifer A. Phipps, Chief Financial Officer · 2026-10-30 — and in the next breath disclaimed them: “we do not rely on the per script metrics to inform our growth strategy or capital allocation decision.” — Jennifer A. Phipps, Chief Financial Officer · 2026-10-30 That is a company introducing a metric and then telling you not to use it. The reason is legible from the prior calls. In the first quarter, gross profit per script was a headline bragging point, up roughly 50%; in the second quarter it was up 28% and management walked analysts through four discrete drivers. This quarter the same GP per script figure gets a disclaimer and a nudge toward dollar-based thinking. The honest read: the mix that lifted the metric — specialty and infusion scripts growing 29%, commercial payer mix rising from roughly a third of incremental growth last year to 45–50% this year — is real and favorable, but it is also a byproduct of LDD launches and infusion expansion whose lapping cadence is not fully in management's control. Disclosing the number creates a comparison the company would rather not own.What management stopped saying out loud
The keyword drift tells the same story. fee-for-service was the top-ranked theme in the first quarter of 2026 and the standing answer to every margin question — the high-margin hub and data-services layer that made LDD economics look better than the headline 1.5% take rate. This quarter, pressed by Pito Chickering on whether LDD economics have moved from 1.5% toward 3% with wraparound services, Jon Rousseau answered that “stability is a really appropriate word” — Jon Rousseau, Executive Officer · 2026-10-30 and pivoted to volume. Wraparound revenue is still mentioned, and it is still growing, but it has slid from thesis to footnote. When a company demotes its own margin story in the same quarter it demotes its per-script metric, that is a coordinated retreat from unit economics toward absolute dollars. That retreat has a date attached to it. 2027. On the Q3 2025 call the framing was a significant brand-to-generic conversion arriving near the end of Q1 2026; in July 2026 Rousseau said the 2027 generic wave would “probably happen later in the year” — Jon Rousseau, Chief Executive Officer · 2026-07-31. On Thursday, Ann Hynes asked directly whether the calendar-2027 generic slate implies a weaker first half, and got: “we are gonna leave our comments regarding 2027 exactly to what we said in the prepared remarks.” — Jon Rousseau, Executive Officer · 2026-10-30 The prepared remarks promise 15–20% organic adjusted EBITDA growth off a 2026 base that is itself growing ~39% — a big promise, delivered with the door firmly shut on the mechanics.Home & community: the IRA headwind becomes a selling point
Here the story genuinely inverted. Home and community pharmacy revenue fell 6% to $553 million on the IRA impact — about $200 million for the full year, with ~$50 million still to hit in Q4 — plus deliberate customer exits. Yet segment profitability rose double digits, and Rousseau called it “another strength of the company” — Jon Rousseau, Executive Officer · 2026-10-30. The mechanism is scale and cost per fill: reworked operations, better service levels, and a pivot toward hospice, senior living, PACE and behavioral from a merely stable skilled-nursing base. This is the single most credible part of the bull case, because it is the one place where the improvement is unambiguously self-inflicted and repeatable — and because the IRA drag mechanically shrinks next year, with management previously sizing 2027's impact at roughly half of 2026's. The provider segment supplied the rest of the beat: revenue up 31%, home health up 50% with $76 million from the acquired Amedisys/LHC branches and 12% organic growth underneath, and provider EBITDA up 16% excluding the acquisitions. The branches are tracking to ~$35 million of 2026 EBITDA, unchanged from the July update — integration is done, not heroic.The $400 million sentence
Buried in A.J. Rice's M&A question is the line that should have moved the stock more than it did:Four months ago the stated ceiling was emphatically smaller — bigger deals were “still probably less than $30 million or $40 million of EBITDA” — Jon Rousseau, Chief Executive Officer · 2026-07-31. Rousseau hedged immediately (deals are hard, they are deliberate, the pipeline is "as full as ever"), and the transcript garbles the precise size band he is now willing to underwrite. But the direction of travel is unmistakable: with leverage at 1.79x and interest coverage rebuilt to 3.5x, BrightSpring is signaling a step up from tuck-ins to platform-sized acquisitions — the exact trade-off that would re-lever a company whose net debt still sits near $1.7 billion. The quieter option is Primary Care. In May the company was “going to be applying to this new lead ACO program... Applications are due in May” — Jon Rousseau, Chief Executive Officer · 2026-05-01. This week it confirmed selection into the next-generation REACH ACO starting January 1, with Rousseau pointing to 2028 for "impactful economics" and stressing zero downside risk. That is value based care as a free option, not a P&L line — and it sits precisely between the pharmacy and provider segments, which is the only place in this portfolio where a genuinely differentiated asset could still be built rather than bought.We could do $400 million of EBITDA in M&A tomorrow. If we wanted to.